2018 Progress and Controversies in Gynecologic Oncology

2018 Progress and Controversies in Gynecologic Oncology

Not a member of My prIME? Join now for instant access.

Meeting Overview

Join the world’s leading gynecologic oncology experts at the 2018 Progress and Controversies in Gynecologic Oncology Conference in Barcelona. Get interactive updates on practice-changing clinical trial data in a format fostering discussions that will impact clinical outcomes for patients.

We look forward to welcoming you to the conference.


Andreas du Bois, MD, PhD
Jonathan Ledermann, BSc, MD, FRCP
Ignace Vergote, MD, PhD
Foto-Prof-du-Bois ledermann-150x150 Ignace-Vergote


Friday, 19 January 2018
Saturday, 20 January 2018

Crowne Plaza Barcelona – Fira Center
Avda Rius I Taulet, 1-3
Barcelona, Spain



Friday, 19 January 2018
Saturday, 20 January 2018



Barcelona, Spain



9.0 European CME Credits

Video Message



Friday, 19 January 2018

13.00 Welcome and introduction

Session I: Endometrial Cancer

13.10 Individualized management of FIGO stage IB-II, G3 endometrial cancer

  • A case for surgery alone ± brachytherapy (10 min)
    Ignace Vergote, MD, PhD
  • A case for surgery + chemotherapy (10 min)
    Mansoor R. Mirza, MD
  • Discussion (15 min)
13.45 Debate: Is there any role for external radiotherapy in FIGO stage III endometrial cancer?
Pro: Remi Nout, MD, PhD
Contra: David Miller, MD, FACOG, FACS

Special Session—The Role of Sentinel Node Procedures in Cervical and Endometrial Cancers

14.20 Update on sentinel node biopsy in endometrial cancer: Feasibility, technique, and impact
Bjørn Hagen, MD, PhD
14.45 Update on sentinel node procedures in cervical cancer: Feasibility, technique, and impact
Nadeem R. Abu-Rustum, MD, FACOG, FACS
15.15 Break

Session II: Lower Gestational Tract and Beyond

15.45 New approaches and developments in the systemic treatment of cervical cancer
Bradley J. Monk, MD, FACS, FACOG
16.15 New approaches and developments in the systemic treatment of endometrial cancer
Andrés Poveda, MD

Special Session—Hot Topics in Gynecologic Oncology

16.45 Update on the management of nonepithelial ovarian cancer (including new genetic data)
Christian Marth, MD, PhD
17.15 Keynote lecture—DNA damage response and resistance mechanisms to PARP inhibitors
Jonathan Ledermann, BSc, MD, FRCP
17.45 Current perspectives on biomarkers for targeted therapies and immunotherapies in gynecologic malignancies
Eric Pujade-Lauraine, MD, PhD
18.15 Day 1 concluding remarks and adjourn

Saturday, 20 January 2018

08.30 Welcome and introduction

Session III: Ovarian Neoplasm I

08.35 How to select the right patient for upfront surgery or chemotherapy
Andreas du Bois, MD, PhD
09.05 Is there still a role for systematic lymphadenectomy at primary debulking surgery for ovarian cancer?
Philipp Harter, MD, PhD
09.35 A critical appraisal of HIPEC in ovarian cancer
Luis Chiva, MD, PhD
10.05 Update on secondary surgery for recurrent ovarian cancer
Stefano Greggi, MD, PhD
10.35 Break

Session IV: Ovarian Neoplasm II

11.05 Interactive clinical case—Front-line therapy: Incorporating targeted therapies
Nicoletta Colombo, MD
11.35 Interactive clinical case—Recurrent disease and platinum seems to be an option
Antonio González-Martín, MD
12.05 Interactive clinical case—Recurrent disease and platinum seems not to be an option
Ana Oaknin, MD, PhD
12.35 Break
13.00 Industry-supported satellite symposium
14.15 Break

Session V: Challenging Issues in Clinical Practice

14.30 The ESGO initiative on quality of centers and education
Denis Querleu, MD
15.00 Tertiary surgery: Is it really an option?
Christina Fotopoulou, MD, PhD
15.30 Palliative care: Surgical and nonsurgical management of acute or subacute bowel obstruction
Giovanni Aletti, MD
16.00 High-risk recurrent gestational trophoblastic disease
Michael Seckl, MD, PhD, FMedSci
16.30 Day 2 concluding remarks and adjourn

    Meeting Chairs

  • Andreas du Bois, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute
    London, United Kingdom
  • Ignace Vergote, MD, PhDUniversity Hospitals Leuven
    Leuven, European Union
  • Scientific Committee

  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St Joseph's Hospital
    Phoenix, Arizona, United States
  • Andrés Poveda, MDInitia Oncology
    Hospital Quirónsalud
    Valencia, Spain
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • Faculty

  • Nadeem R. Abu-Rustum, MD, FACOG, FACSMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Giovanni Aletti, MDEuropean Institute of Oncology
    Milan, Italy
  • Luis Chiva, MD, PhDClínica Universidad de Navarra
    Madrid, Spain
  • Christina Fotopoulou, MD, PhDImperial College London
    London, United Kingdom
  • Antonio González-Martín, MD, PhDClínica Universidad de Navarra
    Madrid, Spain
  • Stefano Greggi, MD, PhDFondazione IRCCS - Istituto Nazionale dei Tumori
    Naples, Italy
  • Bjørn Hagan, MD, PhDTrondheim University Hospital
    Trondheim, Norway
  • Philipp Harter, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Christian Marth, MD, PhDInnsbruck Medical University
    Innsbruck, Austria
  • David Miller, MD, FACOG, FACSUniversity of Texas Southwestern
    Dallas, Texas, United States
  • Mansoor R. Mirza, MDCopenhagen University Hospital
    Copenhagen, Denmark
  • Remi Nout, MD, PhDLeiden University Medical Center
    Leiden, the Netherlands
  • Ana Oaknin, MD, PhDVall d’Hebron Institute of Oncology
    Barcelona, Spain
  • Denis Querleu, MDInstitut Bergonié
    Bordeaux, France
  • Michael Seckl, MD, PhD, FMedSciImperial College
    London, United Kingdom
  • Ate G. J. van der Zee, MD, PhDUniversity Medical Center Groningen
    Groningen, the Netherlands

This meeting has passed.


We are sorry, but the hotel accommodations at the Crowne Plaza Barcelona – Fira Center are sold out.

Cancellation Fee Hotel Rooms
A cancellation fee may apply in the event that a delegate cancels his/her (registration and) hotel accommodation. A written notice of cancellation must be received at [email protected].

  • Until 15 October 2017: 60% of the total amount due is nonrefundable
  • From 16 October 2017: 100% of the total amount due is nonrefundable
  • From 15 December 2017: A modification fee of €15 applies for all changes

The amount of hotel room fees remitted will be refunded after the conference. Substitutions are accepted with written notification. In case of no-shows a 100% cancellation fee of the entire stay will apply.

General Info

All inquiries related to the 2018 Progress and Controversies in Gynecologic Oncology Conference may be addressed to [email protected].

Schenkkade 50, Suite 16
2595 AR The Hague
the Netherlands

Tel.: + 31 70 30 67 190
Fax: + 31 70 33 18 335
Web: www.prIMEoncology.org

Most EU citizens only need their national identity card or passport to enter Spain. Non-EU citizens require a valid passport to enter Spain, but many countries are exempt from tourist visas. It is essential that you check with the Spanish embassy or consulate in your country before traveling. Without exception, passports must be valid for at least six months after your planned date of departure from Spain.

prIME Oncology will not directly contact embassies and consulates on behalf of applicants. It is the sole responsibility of the delegates to look after their visa requirements.

Note: Passport and visa requirements are liable to change at short notice. Travelers are advised to check their entry requirements with their embassy or consulate.

From Barcelona’s main international airport El Prat you can travel different ways to the Conference venue:

TAXI: Barcelona has 11,500 taxis easily identified by their yellow and black color. It takes 15-20 minutes, depending on traffic.

AEROBUS: This special service is clearly signposted at the stops outside the terminal and it takes you to different parts of the city. The Plaza de España stop is the closest to the hotel, approximately a 5-minute walk from the stop to the hotel.

TRAIN: The station is located to the west of the terminal. Trains go to Sants station. From here you can take either the metro 2 stops to Plaza de España and then a 10-15 minute walk or you can take a taxi.

CAR: Take the Castelldefels motorway (C-31) toward Barcelona to Plaza de España. Turn right on Avenida Maria Cristina and drive until you see the National Palace. Turn left on Avenida Rius i Taulet and carry on straight until Lleida Street. The hotel is right on the corner.

Barcelona has a very good public transport system (TMB), with special ten-trip and one-day, two-day, and three-day tickets available for bus, metro, and local trains. You can call a taxi or flag them down in the streets. In many taxis you can also pay by credit card.

Barcelona has a Mediterranean climate with mild, sunny winters, warm summers, and relatively low rainfall. In January, the average temperature is 13° Celsius (55.4° Fahrenheit).

Barcelona is in the Central European time zone (GMT +1).

Spanish and Catalan are the two main languages spoken in Barcelona. English is also widely spoken and to some extent French and German.

The Spanish currency is the Euro (€).

Value-added tax, or VAT, is otherwise known as IVA (impuesto sobre el valor añadido). The IVA is 10% on accommodation and restaurant prices and is usually, but not always, included in quoted prices. On retail goods, the IVA is 21%. IVA-free shopping is available in duty-free shops at all airports for people traveling between EU countries.

Tips are already included in restaurant bills, but it is customary to round up an extra 5% to 10% if you are satisfied with the service. Porters are generally tipped €1 per bag.


This educational activity is supported by:










Several options are available to organizations interested in supporting this conference. For more information, please contact Katie Eustace by phone at +31 70 30 67 190, or by email at [email protected].

Continuing Education

2018 Progress and Controversies in Gynecologic Oncology Conference held in Barcelona, Spain on 19/01/2018-20/01/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Good CME Practice


This activity is provided by prIME Oncology.

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.